1. Introduction {#s0005}
===============

Warfarin has been utilized as an anticoagulant drug for about 60 years but still causing a variety of adverse effects. Routinely, warfarin is monitored by measuring the International Normalized Ratio (INR). The target INR range for most indications of warfarin therapy is 2--3 or 2.5--3.5 ([@b0125], [@b0105]). Keeping patients within target INR range is a challenge. A number of worldwide studies have been conducted to examine the response to warfarin therapy in both ambulatory and hospital settings ([@b0050], [@b0020], [@b0060], [@b0030]). Response to warfarin therapy is patient specific; however, various factors have been reported to alter warfarin response and target INR such as older age, disease states, warfarin dose and influence of other medications ([@b0050], [@b0020], [@b0045], [@b0115], [@b0070], [@b0200], [@b0060], [@b0030]). Conflicting results have been reported for some of these factors such as age, gender and concurrent disease states ([@b0065], [@b0045], [@b0195]). The presence of these factors can keep patients away from achieving target INR range and may cause unnecessary complications. Consequently, monitoring and watching for these influential factors is essential. The objective of this study was to report on the degree to which various factors can hinder achieving target INR range in a sample of adult Egyptian patients on their discharge from hospital care setting.

2. Methods {#s0010}
==========

2.1. Study design and settings {#s0015}
------------------------------

This prospective cross-sectional observational study was conducted at Cardiology Department and Intensive Care Unit (ICU) of Assiut University Hospitals. The study was approved by the Research Ethics Committee at the Faculty of Medicine of Assiut University.

2.2. Study participants {#s0020}
-----------------------

All patients admitted to the Cardiology Department and ICU of Assiut University Hospitals and received warfarin anticoagulation therapy, from July 2013 till January 2014, were included in the study.

2.3. Data collection {#s0025}
--------------------

Patients' data regarding warfarin anticoagulation therapy were collected by reviewing patients' medical records, laboratory measurements of INR and when necessary by interviewing health care professionals as well as patients when some data were missing. Actual warfarin usage and INR measuring laboratories were monitored for one month before designing and formulating data collection sheets.

2.4. Data analysis {#s0030}
------------------

All statistical analyses were performed using IBM SPSS v. 22.

Data are presented as mean (standard deviation), median (interquartile range) or proportions as appropriate. A *p*-value of less than 0.05 was considered significant for all comparisons and all tests were two-tailed.

Independent sample *t*-test with bootstrap was used to compare mean difference between two unrelated groups. Non-parametric tests; Mann--Whitney U test and Kruskal Wallis H test were used to find difference in discharge INRs within the different groups.

Pearson and spearman's rank correlations with bootstrap were used to examine associations between groups.

Multinomial logistic regression was used to examine the influence of different factors on the state of discharge INRs (below, above and within target range groups).

3. Results {#s0035}
==========

3.1. Baseline characteristics {#s0040}
-----------------------------

[Table 1](#t0005){ref-type="table"} shows baseline patients' characteristics. A total of 120 patients were admitted to the Cardiology Department and the ICU. Their mean age was 48.35 years. Seventy-one (59.2%) patients were females. The majority of patients 83 (69.2%) were non-educated, and only 9 (7.5%) patients finished university education. One hundred patients (83.3%) were admitted to the Cardiology Department. Warfarin was most commonly prescribed for atrial fibrillation, 66 (55%) patients.

3.2. Warfarin management metrics {#s0045}
--------------------------------

[Table 2](#t0010){ref-type="table"} shows warfarin management metrics for the patients. Seventy-three patients were previously treated with warfarin before hospital admission and 47 (39.2%) patients were newly initiated warfarin on hospital admission. Prescribed dose, admission and discharge INRs were significantly higher for patients previously treated with warfarin.

3.3. Warfarin prescribed dose in different patient groups {#s0050}
---------------------------------------------------------

[Table 3](#t0015){ref-type="table"} shows difference in prescribed warfarin doses in different patient groups. Elderly patients (⩾60 years) and patients with congestive heart failure were given lower mean prescribed doses than other patients. Patients with mechanical valve replacement were given higher mean prescribed dose than other patients. In patients who were previously treated with warfarin, age was significantly related to current warfarin dose (maintenance dose), *r* = −.31, 95% BCa CI \[−.5, −.08\], *p* = .008.

3.4. Risk of bleeding from warfarin {#s0055}
-----------------------------------

Ten patients suffered from bleeding during hospital stay. All bleeding episodes were considered minor or minimal such as epistaxis, hemoptysis, hematemesis and rectal bleeding. Out of the 10 patients, 2 patients were ⩾65 years (*p* = .69), 2 had congestive heart failure (*p* = .016) and 6 had liver disease (*p* = .003).

3.5. State of discharge INRs {#s0060}
----------------------------

[Table 4](#t0020){ref-type="table"} shows the description of median and interquartile ranges of discharge INR values and analysis of factors potentially affecting them. Newly initiated warfarin patients 27 (22.5%), were more likely to have discharge INR values below target range compared with previously treated patients 24 (20%) (*p* = .012). Also, newly initiated warfarin patients were more likely to have INR values below 1.5 during hospital stay, 13 (27.7%) patients compared with 9 (12.3%) patients respectively (*p* = .034). Of the newly initiated warfarin patients, one patient suffered from new thrombus formation during hospital stay and 6 (5%) patients had INR values ⩾5 during hospital stay compared with 8 (6.7%) previously treated warfarin patients (*p* = .76).

The number of weeks of hospital stay was significantly related to discharge INRs, *r~s~* = .25. 95% BCa CI \[.05--.42\], *p* = .008.

Out of 22 hypertensive patients, 12 (54.6%) were newly initiated warfarin on hospital admission (*p* = .1). Out of the 76 patients who had rheumatic heart disease, 54 (71.1%) patients were previously treated with warfarin (*p* = .003).

Stepwise comparison using Kruskal--wallis test showed that patients with multiple conditions and mechanical valve replacement had significantly higher median discharge INR compared with other indications of warfarin therapy. Similarly, it showed that patients who were admitted from 2 to ⩽3 weeks and ⩾3 weeks had significantly higher median discharge INR values compared with patients admitted for less than 2 weeks.

Out of 52 (43.3%) patients who had infection; 21 (17.5%) patients suffered from active rheumatic heart disease, 15 (12.5%) patients suffered from chest infection, 13 (10.8%) patients suffered from infective endocarditis and 3 (2.5%) patients suffered from urinary tract infection.

3.6. Multinomial logistic regression of factors that potentially affect discharge INRs {#s0065}
--------------------------------------------------------------------------------------

Multinomial logistic regression whereby clinical and other patient characteristics were included in the model ([Table 5](#t0025){ref-type="table"}) showed that the best predictors of achieving below target INR range relative to within target INR range were; shorter hospital stay periods (0.82 times less likely for every day increase, *p* = .006), being a male patient (2.85 times more likely, *p* = .039), infection (0.21 times less likely, *p* = .003) and patients newly initiated warfarin therapy on hospital admission (3.73 times more likely, *p* = .016).

Whereas, the best predictor of achieving above target relative to within target INR values was; longer duration of hospital stay (1.12 times more likely for every day increase, *p* = .048).

4. Discussion {#s0070}
=============

The present study investigated the potential effect of various factors on warfarin response.

We observed that warfarin initiation dose was not prescribed according to the guidelines. The starting dose of the majority of patients who were newly initiated warfarin in the hospital was 3 mg. Doses lower than 3 mg were initiated in the elderly (\>70 years) and liver disease patients. When initiating warfarin therapy, loading dose is usually given to rapidly elevate INR and reduce the time needed to achieve target INR range. Studies have suggested that warfarin initiation dose between 5 and 10 mg is appropriate and effective ([@b0010]). Some studies have suggested that 10 mg loading dose is not superior to 5 mg loading dose and that 5 mg dose may avoid the development of potential hyper-coagulate state ([@b0095], [@b0035]). However, other studies recommended 10-mg dosing nomogram over 5-mg nomogram because it allowed more rapid achievement of target INR and it was safe ([@b0130], [@b0160]). Initiation dose ⩽5 mg is appropriate in the elderly, patients with liver disease, impaired nutrition, congestive heart failure and in patients with increased risk of bleeding ([@b0090], [@b0075], [@b0010]). This may explain why newly initiated warfarin patients were more likely to have discharge INR values below target range than those who previously initiated it. This may also explain why newly initiated warfarin patients were more likely to have INR values below 1.5 during hospital stay. It was reported that values of INR below 1.5 increase the risk of thromboembolism ([@b0180], [@b0165]).

Elderly patients (⩾60 years) had lower median INR than adult and young patients. Although the results were not statistically significant, our data were inconsistent with published studies. In a USA study conducted on 530 patients, the prothrombin time ratio, when adjusted for dose, was significantly increased in older patients ([@b0090]). Moreover, older age was found in a number of studies to increase the risk of INR ⩾5 and warfarin-associated bleeding ([@b0070], [@b0200], [@b0060]). However, age did not appear to be an important determinant of risk for warfarin-associated bleeding except may be for age ⩾80 years ([@b0065]). Low Median INR and low incidence of bleeding events in our elderly patients are probably due to that elderly patients were given smaller mean prescribed warfarin doses than others. In patients who were previously treated with warfarin, age was significantly related to the maintenance dose. This was consistent with other published studies that older patients require lower maintenance warfarin doses ([@b0175], [@b0075]).

Women had a slightly non-significant higher median discharge INR compared with men. Women were less likely to be discharged with INR values below target range. A retrospective, longitudinal cohort study conducted on 12,006 patients showed that patients with respiratory illness, as well as women, patients with cancer and those with an elevated baseline INR, are at high risk of anticoagulation and should have additional INR monitoring ([@b0030]). Other studies showed that women required lower maintenance doses of warfarin than men ([@b0005], [@b0075], [@b0205]). However, a retrospective study was conducted on 403 males and 403 females found that men had significantly higher baseline INR than women in patients without any known liver disease or anticoagulant medication ([@b0195]). The effect of gender on INR values and warfarin response may require further investigation.

Patients with multiple conditions and mechanical valve replacement (especially MVR and DVR) had the highest median discharge INR compared with others. This is probably due to these patients require higher target INR of 2.5--3.5 compared with others (mainly from 2 to 3). Consequently, they were given larger mean prescribed warfarin doses to achieve higher target INR.

Patients who were admitted for more than two weeks had the highest median INR values. Also, the number of weeks of hospital stay was significantly related to discharge INRs. Our finding showed that longer duration of hospital stay decreased the likelihood of having INR values below target range and increased the likelihood of having INR values above target range. This may suggest that longer hospital stay periods are required to achieve a desired change in the INR values and patients who were discharged with INR values below target range did not stay for adequate time to have their INRs properly adjusted. Moreover, patients who stayed for longer hospital periods had deteriorated health conditions which might affect discharge INRs or that they were kept longer to have their INRs properly adjusted before discharge.

Hypertensive patients had a lower median INR before discharge than other patients. There has been no reported evidence in the literature on the effect of elevated blood pressure on INR or warfarin pharmacodynamics and pharmacokinetics. Also, our subjects did not take any antihypertensive medication that can interact with warfarin. However, the reason for this may be due to the fact that more than half of hypertensive patients were newly initiated warfarin on hospital admission. As mentioned before, newly initiated warfarin patients were more likely to have discharge INR values below target range than those who previously initiated it. In general, the use of warfarin is contraindicated in patients with malignant, severe and uncontrolled hypertension, due to increased risk of intracerebral hemorrhage. Warfarin may be needed to be used cautiously and INR should be monitored more frequently in patients with severe or uncontrolled hypertension ([@b0155]).

Patients with congestive heart failure had a lower median discharge INR and a lower incidence of bleeding events compared with other patients. This was not consistent with published reports and studies which have demonstrated that patients with congestive heart failure have increased response to warfarin therapy and increased risk of bleeding and high INR ([@b0170], [@b0050], [@b0115], [@b0185]). The suggested mechanism for increased warfarin response in congestive heart failure patients is probably due to hepatic congestion and dysfunction ([@b0185]). The liver is the site for the synthesis of vitamin K clotting factors. Oxygen limitation theory is another suggested mechanism ([@b0140], [@b0115]). Also, malnutrition is common in congestive heart failure patients ([@b0025]). This may be associated with decreased dietary intake of vitamin K. The decreased discharge INR for congestive heart failure patients in our study was probably due to that they were given lower mean prescribed warfarin doses compared with others.

Patients with liver disease were more likely to experience bleeding episodes during their hospital stay. This was consistent with other published studies where liver disease was associated with increased risk of hemorrhage ([@b0135], [@b0210]). Liver disease is well documented to affect warfarin response and cause defective hemostasis and prolongation of prothrombin time ([@b0055], [@b0150], [@b0045]). As mentioned above, initiation doses of ⩽5 mg are appropriate for patients with liver disease and signs of bleeding should be observed and monitored.

Patients with rheumatic heart disease had a higher median discharge INR compared with other patients. This could be explained by that most rheumatic heart disease patients were diagnosed before admission and were previously treated with warfarin. As mentioned before, previously treated warfarin patients were more likely to have higher discharge INR values compared with newly initiated patients. Many of rheumatic heart disease patients had prosthetic valve replacement (mainly MVR and DVR). Warfarin was given to these patients targeting higher INR values of 2.5--3.5. Thus, rheumatic heart disease patients were given higher mean prescribed doses than others to achieve higher target INR values. Also, some patients with active rheumatic heart disease were given broad spectrum antibiotic amoxicillin/clavulanate. Isolated cases of increased INR were seen in patients taking warfarin concurrently with amoxicillin/clavulanate ([@b0040], [@b0120]).

Patients with infection had a higher median discharge INR compared with other patients. They were less likely to be discharged with INR values below target range. All of these patients received antibiotics and the higher median INR is probably due to potential interaction of antibiotics with warfarin. Patients with infective endocarditis were prescribed amoxicillin/clavulanate for up to 12 g daily. Antibiotics were reported to potentially interact with warfarin ([@b0085], [@b0080]). Another possible reason is that fever associated with infection increased response of warfarin by increasing catabolism of vitamin K dependent coagulation factors ([@b0100]). Also, there is a potential interaction between paracetamol prescribed for fever and warfarin ([@b0110], [@b0145]). A study was conducted on 12,006 patients found that acute upper respiratory tract infection increases the risk of excessive anticoagulation independent of antibiotic use ([@b0030]). Patients with infection should be closely monitored for potential increased response of warfarin and drug interactions.

5. Conclusion {#s0075}
=============

Various factors were found to affect warfarin response. Days of hospital stay significantly predicted whether patients were discharged with INR values below or above target range relative to within target range. Gender, concurrent infection and new initiation of warfarin therapy significantly predicted whether patients were discharged with INR values below target range relative to within target range. Initiating warfarin therapy without giving loading doses can decrease the risk of bleeding events during hospital stay. However, it increases the incidence of having INR values ⩽1.5 and consequently increases the risk of new thrombus formation. Also, it increases the odds for the patients to be discharged with INR values below target range or can increase the duration of hospital stay to get the INRs properly adjusted. Following warfarin dosing nomograms and careful monitoring of the effect of various factors on warfarin response should be greatly considered.

6. Limitations {#s0080}
==============

One of the strengths of our study is that we investigated the simultaneous effect of various factors on warfarin response in hospitalized patients. But, we were not encountered with the genetic effect of the subjects. However, previous studies on the pharmacogenomics of warfarin in the Egyptian community were reported which found that genetic factors are important determinant of warfarin dose requirement ([@b0190], [@b0015]).

Peer review under responsibility of King Saud University.

###### 

Patients' baseline characteristics.

  ------------------------------------- -------------
  Total number of the patients          120 (100%)
  Mean age                              48.4 ± 15.5
  Sex                                   
   Males                                49 (40.8%)
   Females                              71 (59.2%)
  Education                             
   Non-educated                         83 (69.2%)
   Primary education                    17 (14.2%)
   Vocational education                 11 (9.2%)
   University education                 9 (7.5%)
  Place of admission                    
   Cardiology department                100 (83.3%)
   Cardiovascular Intensive Care Unit   20 (16.7%)
  Indication for warfarin therapy       
   Atrial Fibrillation                  66 (55%)
   Mechanical valve replacement         11 (9.2%)
    MVR                                 5
    AVR                                 1
    DVR                                 5
   Cardiomyopathy                       13 (10.8%)
   Thromboembolism                      5 (4.2%)
    DVT                                 3
    PE                                  2
   Myocardial infarction                4 (3.3%)
   Stroke                               1 (0.8%)
   Multiple conditions                  17 (14.2%)
   Other conditions                     3 (2.5%)
  ------------------------------------- -------------

MVR: mitral valve replacement, AVR: atrial valve replacement, DVR: double valve replacement, DVT: deep venous thrombosis, PE: pulmonary embolism. Other conditions refer to clinical indications rather than reported in the table.

###### 

Warfarin management metrics.

                                                     Patients previously treated with warfarin *n* = 73 (60.8%)   Patients newly initiated warfarin on hospital admission *n* = 47 (39.2%)   *p*-Value                               BCa 95% CI
  -------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------- --------------------------------------- -------------
  Prescribed dose[c](#tblfn3){ref-type="table-fn"}   4.1 mg (±2.2)                                                2.8 mg (±0.9)                                                              .001[b](#tblfn2){ref-type="table-fn"}   0.76, 1.86
  Discharge dose                                     4 mg (±2.6)                                                  3.5 mg (±1.2)                                                              .16                                     −0.18, 1.28
  Days of hospital stay                              9.2 days (±5)                                                10 days (±8.3)                                                             .56                                     −3.77, 1.98
  Number of INR measurements                         3.4 (±2.8)                                                   3.7 (±4.4)                                                                 .64                                     −2.09, 1.12
  Admission INRs                                     2.7 (±2.2)                                                   1.3 (±0.3)                                                                 .001[b](#tblfn2){ref-type="table-fn"}   0.90, 1.92
  Discharge INRs                                     2.9 (±1.9)                                                   2.2 (±1.5)                                                                 .02[a](#tblfn1){ref-type="table-fn"}    0.07, 1.34

BCa 95% CI: Bias corrected and accelerated 95% confidence interval.

Significant at *p* \< .05.

Significant at *p* \< .01, bootstrap for independent samples *t*-test based on 1000 bootstrap samples..

Prescribed dose means current dose for previously treated warfarin patients and initiation dose for newly initiated warfarin patients.

###### 

Comparing the mean prescribed warfarin doses between study groups.

  Character                                                       Number of patients (%) *N* = 120 (100%)   Mean prescribed dose (SD)   *p*-Value                               BCa 95% CI
  --------------------------------------------------------------- ----------------------------------------- --------------------------- --------------------------------------- --------------
  Age                                                                                                                                   .004[a](#tblfn4){ref-type="table-fn"}   −1.55, −0.34
   Age ⩾ 60                                                       29 (24.2%)                                2.9 (±1.1)                                                          
   Age \< 60                                                      91 (75.8%)                                3.8 (±2.1)                                                          
  Mechanical valve replacement[b](#tblfn5){ref-type="table-fn"}                                                                         .002[a](#tblfn4){ref-type="table-fn"}   1.23, 3.11
   Yes                                                            25 (20.8%)                                5.3 (±2.6)                                                          
   No                                                             95 (79.2%)                                3.2 (±1.4)                                                          
  Congestive heart failure                                                                                                              .003[a](#tblfn4){ref-type="table-fn"}   −1.96, −0.61
   Yes                                                            70 (58.3%)                                3.1 (±1.5)                                                          
   No                                                             50 (41.7%)                                4.3 (±2.2)                                                          

BCa 95% CI: Bias corrected and accelerated 95% confidence interval.

Significant at *p* \< .01, bootstrap for independent samples *t*-test based on 1000 bootstrap samples.

All patients with mechanical valve replacement including those with multiple conditions.

###### 

Factors that potentially affect median and interquartile ranges of the discharge INR values.

  Character                               Number of patients (%) *N* = 120   Median INR (IQR)                     *p*-Value
  --------------------------------------- ---------------------------------- ------------------------------------ ---------------------------------------
  Sex                                                                                                             .27
   Male                                   49 (40.8%)                         1.9 (1.5--2.5)                       
   Female                                 71 (59.2%)                         2.1 (1.6--3.1)                       
  Age category                                                                                                    .29
   Young                                  2 (1.7%)                           3.4                                  
   Adult                                  89 (74.2%)                         2.1 (1.6--3)                         
   Elderly                                29 (24.2%)                         1.8 (1.4--3)                         
  Education                                                                                                       .12
   Non-educated                           83 (69.2%)                         2.1 (1.5--3.1)                       
   Primary education                      17 (14.2%)                         2.2 (1.8--2.8)                       
   Vocational education                   11 (9.2%)                          3.3 (1.9--3.7)                       
   University education                   9 (7.5%)                           1.6 (1.2--2.1)                       
  Place of admission                                                                                              .88
   Cardiovascular Department              100 (83.3%)                        2.1 (1.6--2.9)                       
   Cardiovascular ICU                     20 (16.7%)                         2.2 (1.3--3.1)                       
  Indication for warfarin therapy                                                                                 .01[a](#tblfn6){ref-type="table-fn"}
   Atrial Fibrillation                    66 (55%)                           1.9 (1.5--2.7)                       
   Mechanical valve                       11 (9.2%)                          2.6 (2.3--3.5)                       
   Cardiomyopathy                         13 (10.8%)                         1.7 (1.4--2.2)                       
   Thromboembolism                        5 (4.2%)                           1.8 (1.7--8.8)                       
   MI                                     4 (3.3%)                           1.7 (1.2--2)                         
   Multiple conditions                    17 (14.2%)                         3.1 (2.1--4.4)                       
   Other conditions                       3 (2.5%)                           2.6                                  
  Number of weeks of hospital stay                                                                                .024[a](#tblfn6){ref-type="table-fn"}
   \<1 week                               45 (37.5%)                         1.9 (1.3--2.7)                       
   1--\<2                                 55 (45.8%)                         2.1 (1.6--2.8)                       
   2--\<3                                 14 (11.7%)                         2.4 (1.9--4.1)                       
   ⩾3                                     6 (5%)                             3.8 (2.4--4.4)                       
  State of warfarin therapy                                                                                       .001[b](#tblfn7){ref-type="table-fn"}
   Previously treated                     73 (60.8%)                         2.3 (1.8--3.4)                       
   Newly initiated                        47 (39.2%)                         1.7 (1.3--2.3)                       
  Comorbidities                                                                                                   
   Hypertension                           22 (18.3%)                         1.7 (1.2--2.5) vs. 2.1 (1.6--3.1)    .038[a](#tblfn6){ref-type="table-fn"}
   Diabetes mellitus                      23 (19.2%)                         1.7 (1.3--2.9) vs. 2.1 (1.6--3)      .13
   Congestive heart failure               70 (58.3%)                         1.9 (1.4--2.3) vs. 2.6 (1.7--4)      .006[b](#tblfn7){ref-type="table-fn"}
   Rheumatic heart disease                76 (63.3%)                         2.3 (1.7--3.2) vs. 1.7 (1.4--2.3)    .006[b](#tblfn7){ref-type="table-fn"}
   Non-rheumatic valvular heart disease   10 (8.3%)                          1.7 (1.2--2.5) vs. 2.1 (1.6--3)      .14
   Ischemic heart disease                 20 (16.7%)                         1.7 (1.3--2.3) vs. 2.1 (1.6--3.1)    .05
   Liver disease                          23 (19.2%)                         2.1 (1.3--2.6) vs. 2.1 (1.5--3)      .62
   Infection                              52 (43.3%)                         2.38 (1.9--3.6) vs. 1.8 (1.4--2.4)   .004[b](#tblfn7){ref-type="table-fn"}
   Other comorbid conditions              43 (35.8%)                         2.1 (1.6--3) vs. 2.1 (1.5--2.9)      .79

*p*-values were generated using non-parametric tests (Mann--Whitney U and Kruskal Wallis tests) as appropriate.

IQR: interquartile range, ICU: Intensive Care Unit, MI: myocardial infarction.

Significant at *p* \< .05.

Significant at *p* \< .01.

###### 

Potential factors affecting state of discharge INR values: multivariate multinomial logistic regression.

  Predictor                                                                     Beta (SE)                                       95% CI for odds ratio          
  ----------------------------------------------------------------------------- ----------------------------------------------- ----------------------- ------ ------
  *Below target range vs. within target range*                                                                                                                 
  Intercept                                                                     0.69 (1.39)                                                                    
  Age                                                                           0.02 (0.02)                                     0.99                    1.02   1.05
  Prescribed warfarin dose                                                      0.18 (0.14)                                     0.9                     1.19   1.58
  Days of hospital stay                                                         −0.2 (0.07)[b](#tblfn9){ref-type="table-fn"}    0.72                    0.82   0.94
  Gender (female vs. male)                                                      −1.06 (0.51)[a](#tblfn8){ref-type="table-fn"}   0.13                    0.35   0.95
  Congestive heart failure                                                      0.54 (0.55)                                     0.58                    1.72   5.08
  Liver disease                                                                 0.09 (0.67)                                     0.3                     1.1    4.05
  Infection                                                                     −1.58 (0.54)[b](#tblfn9){ref-type="table-fn"}   0.07                    0.21   0.59
  State of warfarin therapy (newly initiated vs. previously treated patients)   1.32 (0.55)[a](#tblfn8){ref-type="table-fn"}    1.28                    3.73   10.9
  *Above target range vs. within target range*                                                                                                                 
  Intercept                                                                     −1.66 (1.64)                                                                   
  Age                                                                           0.01 (0.02)                                     0.96                    1.01   1.05
  Prescribed warfarin dose                                                      0.08 (0.15)                                     0.8                     1.08   1.46
  Days of hospital stay                                                         0.11 (0.06)[a](#tblfn8){ref-type="table-fn"}    1                       1.12   1.24
  Gender (female vs. male)                                                      −0.31 (0.6)                                     0.23                    0.73   2.39
  Congestive heart failure                                                      −0.58 (0.6)                                     0.17                    0.56   1.81
  Liver disease                                                                 −0.98 (0.83)                                    0.07                    0.37   1.88
  Infection                                                                     0.19 (0.59)                                     0.37                    1.21   3.89
  State of warfarin therapy (newly initiated vs. previously treated patients)   −0.45 (0.74)                                    0.15                    0.64   2.73

Note. Within target range group was used as the reference groups. *R*^2^ = .351 (Cox & Snell), .401 (Nagelkerke). Model *χ*^2^(16) = 49.37, *p* \< .001.

*p* \< .05.

*p* \< .01.
